2016 EUROPE NORDIC U.S. SYMPOSIUM. New Frontiers in Antibacterial Resistance Research

Transcription

1 2016 EUROPE NORDIC U.S. SYMPOSIUM New Frontiers in Antibacterial Resistance Research January 20-21, 2016 Venue: Karolinska institutet Stockholm, Sweden Objectives: Antibacterial resistance is accelerating at an alarming pace, leading to a global increase in morbidity and mortality due to resistant bacterial infections. The US National Institute of Allergy and Infectious Diseases and the EU Joint Programming Initiative on AMR are committed to funding basic, translational and clinical research to address this growing public health threat. New Frontiers in Antibacterial Resistance Research will increase the Trans- Atlantic dialogue and scientific collaboration to enhance research addressing antibacterial resistance. The workshop objectives are: 1. To discuss cutting-edge approaches to address antibacterial resistance 2. To foster communication and research collaborations among scientists in the US and the EU 3. To share information on funding opportunities to advance antibacterial resistance research Sponsors: The EU Joint Program Initiative for Antimicrobial Research The Swedish Research Council The U.S. National Institutes of Health: National Institute of Allergy and Infectious Diseases, Fogarty International Center Participants: Approximately 80 invited scientific leaders and researchers drawn primarily from leading European, Nordic and U.S. institutions, as identified by the Scientific Planning Committee DAY ONE 8:00 8:30 Registration 1

2 WELCOMING REMARKS 8:30 9:00 Professor Mats Ulfendahl, Secretary General, Swedish Research Council U.S. Ambassador or other (TBD) Other Sponsor or WHO (TBD) OPENING PLENARY (Broad Overview of Nordic, European and US activities and mechanisms to address AR research) KEYNOTE PRESENTATION 9:00 9:30 Antibacterial Resistance: Overview of the Threat Fernando Baquero, Ramón y Cajal University Hospital 9:30-10:00 Antibacterial Resistance: Research Efforts Henry F. Chambers, University of California San Francisco School of Medicine, USA 9:50 10:20 Current AMR Activities- TATFAR, CARB, etc. NIH/NIAID Dennis M. Dixon JPIAMR Mats Ulfendahl or board member European Commission, DG-Research Arjon Van Hengel 10:20 10:50 Tea and Coffee Break SESSION 1 MOLECULAR EPIDEMIOLOGY AND EVOLUTION OF ANTIBACTERIAL RESISTANCE Moderator: James M. Musser, Methodist Hospital System, Houston, TX USA Rapporteur: Laura Plant 2

3 10:50-11:15 EU Molecular Epi Jordi Vila Estape, University of Barcelona 11:15 11:40 Molecular Epidemiology of Carbapenem-resistant Enterobacteriaceae in the US Barry N. Kreiswirth, Public Health Research Institute, Rutgers New Jersey Medical School 11:40 12:05 Ecology of emerging resistance and genetic evidence of inter-species cross-over Lance B. Price, George Washington University 12:05 12:45 Discussion/Questions 12:45 13:45 Lunch with presentation on Research Funding Opportunities supported by NIH Jane Knisely, NIH/NIAID SESSION 2 APPROACHES TO COMBAT ANTIBACTERIAL RESISTANCE: ENABLING TECHNOLOGIES Moderator: Otto Cars Rapporteur: Maria Pränting 13:45 14:10 Systems Biology and Antibacterial Resistance Roy Kishony, Technion University and Harvard Medical School 14:10 14:35 Insights into Gram-negative permeability and efflux Michael Mourez, SANOFI 14:35 15:00 Pharmacological approaches to address AR George Drusano, University of Florida, USA 15:00 15:30 Discussion/Questions 15:30 16:00 Tea and Coffee Break 3

4 16:00 16:25 Diagnostic Technologies to Guide the Use of Narrow Spectrum Therapeutics Herman Goossens, University of Antwerp 16:25 16:50 New Tools for Identification of Novel Natural Product Antibiotics TBC 16:50 17:30 Discussion/Questions DAY TWO 8:00 8:30 Registration SESSION 3 NON-TRADITIONAL APPROACHES TO PREVENT AND TREAT AR INFECTIONS Moderator: Frank DeLeo (NIAID/NIH) Rapporteur: Laura Plant 8:30 8:55 Modulating the Immune System to Combat Bacterial Infection Birgitta Agerberth, Karolinska Institutet 8:55 9:20 Bacterial vaccines Olaf Schneewind, University of Chicago, USA 9:20-9:55 Monocolonal Antibodies for Prevention and Treatment Steven J. Projan, MedImmune, USA 9:55 10:30 Discussion/Questions 10:30 10:50 Tea and Coffee Break 10:50 11:15 Anti-Virulence Strategies Fredrik Almqvist, Umea University, Sweden 4

5 11:15-11:40 Synthetic Micobiota: An Ecobiological Approach Matthew Henn, Seres Therapeutics 11:40 12:05 Bacteriophage Therapy Anders Nilsson, The Wenner-Gren Institute, Stockholm University, Sweden 12:05-12:30 Predatory Bacteria Ilana Kolodkin-Gal, Weizmann Institute of Science, Israel 12:30 13:00 Discussion/Questions 13:00 14:00 Lunch with presentation on research funding opportunities supported by European funders Arjon Van Hengel, European Commission DG-Research Laura Marin, JPIAMR SESSION 4 Clinical Research on Antibacterial Resistance Moderator: Niels Frimodt-Møller, Rigshospitalet Rapporteur: Dennis Dixon, NIH 14:00 14:30 Overview of challenges in the conduct of interventional trials to address antibacterial resistance John Rex, AstraZeneca 14:30-14:50 The Antibacterial Resistance Leadership Group Vance Fowler, Duke University, USA 5

6 14:50-15:10 IMI ND4BB COMBACTE Marc J M Bonten University Medical Center Utrecht, COMBACTE managing entity 15:10 15:30 Discussion/Questions 15:30-15:50 Tea and Coffee Break SESSION 5 SUMMARY AND CLOSING REMARKS 15:50 17:00 Rapporteur Summaries and General Discussion of Promising Collaborative Research Activities 17:00 17:15 Closing Remarks from NIH and SRC 6